The Cytosorbents Corp (CTSO) Given Consensus Rating of “Buy” by Brokerages

The Cytosorbents Corp (CTSO) Given Consensus Rating of “Buy” by Brokerages

Shares of Cytosorbents Corp (OTCMKTS:CTSO) have received a consensus recommendation of “Buy” from the five analysts that are currently covering the firm. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $15.05.

Several research analysts recently weighed in on the stock. B. Riley assumed coverage on shares of Cytosorbents Corp in a research note on Tuesday, October 11th. They set a “buy” rating and a $11.25 price objective on the stock. Maxim Group set a $8.00 price objective on shares of Cytosorbents Corp and gave the stock a “buy” rating in a research note on Thursday, September 8th. Aegis started coverage on shares of Cytosorbents Corp in a research note on Wednesday, October 26th. They issued a “buy” rating and a $20.00 price target on the stock. HC Wainwright set a $12.00 price target on shares of Cytosorbents Corp and gave the company a “buy” rating in a research note on Tuesday, October 11th. Finally, Brean Capital started coverage on shares of Cytosorbents Corp in a research note on Tuesday, October 4th. They issued a “buy” rating and a $24.00 price target on the stock.

Shares of Cytosorbents Corp (OTCMKTS:CTSO) opened at 5.90 on Wednesday. The firm’s market cap is $150.08 million. Cytosorbents Corp has a 12-month low of $3.11 and a 12-month high of $8.10. The stock’s 50 day moving average is $5.95 and its 200-day moving average is $4.95.

Cytosorbents Corp (OTCMKTS:CTSO) last issued its earnings results on Tuesday, August 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.03. The firm had revenue of $1.90 million for the quarter, compared to the consensus estimate of $2.18 million. On average, analysts anticipate that Cytosorbents Corp will post ($0.40) EPS for the current fiscal year.

Related posts

Leave a Comment